Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Cerebral Therapeutics

Request full access

A Clinical-stage pharmaceutical company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy

Aurora, United StatesFounded 2010Biotech & Life Sciences

About Cerebral Therapeutics

Cerebral Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, directing its efforts toward developing treatments for severe neurological conditions. The company was founded in February 2018 by Dr. Dan Abrams, who brings a unique combination of experience as both a neurosurgeon and a psychiatrist. His prior experience includes founding Sierra Neuropharmaceuticals and serving as the head of Neurosurgery at St. Joseph's Hospital in Denver, providing him with extensive expertise in implantable CNS devices and pharmaceuticals for brain diseases.

The company's core focus is on addressing refractory epilepsy, a condition where patients' seizures are not controlled by existing medical or surgical options. Cerebral Therapeutics is pioneering the use of intracerebroventricular (ICV) therapies, a method that delivers medication directly into the central nervous system. This approach is designed to overcome the limitations of conventional oral medications by bypassing the blood-brain barrier, which can increase the drug's effectiveness at the target site while minimizing systemic side effects and improving patient adherence to treatment regimens. The business model centers on the development and eventual commercialization of these novel drug-device combination therapies. Collaborations with other biopharmaceutical companies are also part of their strategy to advance their pipeline.

The company's main product candidate is CT-010, a proprietary formulation of valproic acid delivered via its proprietary ICVRx™ technology. This system uses a surgically implanted and refillable catheter and pump to provide a continuous, micro-dose infusion of the therapeutic drug directly to the ventricles of the brain. The company has advanced CT-010 into clinical trials, including a Phase 2b double-blind, randomized, placebo-controlled study for treating uncontrolled seizures in patients with medically refractory epilepsy. The company has successfully raised significant capital to fund these developments, including a $40 million Series C financing round in June 2022, bringing its total funding to over $85 million across multiple rounds from investors such as Lynx Capital, RA Capital Management, and Vivo Capital.

Source: Dealroom company data

At a glance

Status
Operational
Employees
20
Open positions
None listed
Dealroom signal
57.7/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GRANTOther financing Jul 2022 $32K — Innovation Connections —
SERIES COther financing Jun 2022 $40M $160M RA Capital Management · Lynx1 Capital Management · Granite Point Capital · Vivo Capital ↗
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Cerebral Therapeutics website traffic

Latest recorded traffic for Cerebral Therapeutics is 2.2K monthly website visits, down 4.3% over the last three months. Cerebral Therapeutics's team grew 0% over the past year.

Latest monthly visits2.2K 3-month web change-4.3% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Cerebral Therapeutics in the Aurora ecosystem

Live from Dealroom

The Cerebral Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Innovation Connections

Series A3 investors entered at this stage

Series B and later2 investors entered at this stage

Other known investors1 additional known investor

  • University of Colorado
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Aurora HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Cerebral Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cerebral Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.